(January 26, 2015) Use of the PARP inhibitor veliparib in combination with oral cyclophosphamide did not result in an improvement in response rate or median progression-free survival compared with treatment with cyclophosphamide alone, according to a phase II study evaluating patients with high-grade serous ovarian cancer, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers. The research was reported in Clinical Cancer Research.
However, the study did demonstrate that oral cyclophosphamide was well-tolerated among this patient population and was associated with responses and prolonged disease stabilization.
Read a short article about this research here; read the scientific abstract here.
